NUVATION BIO INC CLASS A (NUVB) — insider trading
Health Care · NYSE
NUVATION BIO INC CLASS A (NUVB) has 32 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase and 6 open-market sales among the most recent 32 (latest 2026-08-19).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-19 | Hattersley Gary | Officer (CHIEF SCIENTIFIC OFFICER) | Option exercise / conversion (derivative) | 100,000 | — | $0 | Form 4 |
| 2026-08-19 | Hattersley Gary | Officer (CHIEF SCIENTIFIC OFFICER) | Open-market sale | 100,000 | $7.09 | $709.2K | Form 4 |
| 2026-08-19 | Hattersley Gary | Officer (CHIEF SCIENTIFIC OFFICER) | Option exercise / conversion | 100,000 | $1.87 | $187.0K | Form 4 |
| 2026-07-15 | Sauvage Philippe | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 1 | — | $0 | Form 4 |
| 2026-07-15 | Sauvage Philippe | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 39,999 | — | $0 | Form 4 |
| 2026-07-15 | Sauvage Philippe | Officer (Chief Financial Officer) | Option exercise / conversion | 1 | $1.97 | $2 | Form 4 |
| 2026-07-15 | Sauvage Philippe | Officer (Chief Financial Officer) | Option exercise / conversion | 39,999 | $2.17 | $86.8K | Form 4 |
| 2026-06-23 | Sauvage Philippe | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 47,668 | — | $0 | Form 4 |
| 2026-06-23 | Sauvage Philippe | Officer (Chief Financial Officer) | Open-market sale | 47,668 | $6.01 | $286.4K | Form 4 |
| 2026-06-23 | Sauvage Philippe | Officer (Chief Financial Officer) | Option exercise / conversion | 47,668 | $2.17 | $103.4K | Form 4 |
| 2026-06-23 | Wentworth Kerry | Officer (CHIEF REGULATORY OFFICER) | Option exercise / conversion (derivative) | 63,000 | — | $0 | Form 4 |
| 2026-06-23 | Wentworth Kerry | Officer (CHIEF REGULATORY OFFICER) | Open-market sale | 63,000 | $6.02 | $379.2K | Form 4 |
| 2026-06-23 | Wentworth Kerry | Officer (CHIEF REGULATORY OFFICER) | Option exercise / conversion | 63,000 | $2.93 | $184.6K | Form 4 |
| 2026-06-23 | Markel Stacy | Officer (CHIEF PEOPLE OFFICER) | Option exercise / conversion (derivative) | 34,620 | — | $0 | Form 4 |
| 2026-06-23 | Markel Stacy | Officer (CHIEF PEOPLE OFFICER) | Option exercise / conversion (derivative) | 90,380 | — | $0 | Form 4 |
| 2026-06-23 | Markel Stacy | Officer (CHIEF PEOPLE OFFICER) | Open-market sale | 125,000 | $6.03 | $753.2K | Form 4 |
| 2026-06-23 | Markel Stacy | Officer (CHIEF PEOPLE OFFICER) | Option exercise / conversion | 34,620 | $1.74 | $60.2K | Form 4 |
| 2026-06-23 | Markel Stacy | Officer (CHIEF PEOPLE OFFICER) | Option exercise / conversion | 90,380 | $1.87 | $169.0K | Form 4 |
| 2026-06-09 | Mashal Robert | Director | Open-market purchase | 25,000 | $4.73 | $118.3K | Form 4 |
| 2026-05-21 | Cui Xiangmin | Director | Grant / award / vesting (derivative) | 123,397 | — | $0 | Form 4 |
| 2026-05-21 | Bazemore Robert B | Director | Grant / award / vesting (derivative) | 123,397 | — | $0 | Form 4 |
| 2026-05-21 | BLICKENSTAFF KIM D | Director | Grant / award / vesting (derivative) | 123,397 | — | $0 | Form 4 |
| 2026-05-21 | FALBERG KATHRYN E | Director | Grant / award / vesting (derivative) | 123,397 | — | $0 | Form 4 |
| 2026-05-21 | Mashal Robert | Director | Grant / award / vesting (derivative) | 123,397 | — | $0 | Form 4 |
| 2026-05-21 | VERNON W ANTHONY | Director | Grant / award / vesting (derivative) | 123,397 | — | $0 | Form 4 |
| 2026-04-17 | Liu Dongfang | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-04-17 | Liu Dongfang | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 50,000 | $5.02 | $251.0K | Form 4 |
| 2026-04-17 | Liu Dongfang | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion | 50,000 | $1.94 | $97.0K | Form 4 |
| 2026-04-17 | Wentworth Kerry | Officer (CHIEF REGULATORY OFFICER) | Option exercise / conversion (derivative) | 36,750 | — | $0 | Form 4 |
| 2026-04-17 | Wentworth Kerry | Officer (CHIEF REGULATORY OFFICER) | Open-market sale | 36,750 | $5.01 | $184.3K | Form 4 |
| 2026-04-17 | Wentworth Kerry | Officer (CHIEF REGULATORY OFFICER) | Option exercise / conversion | 36,750 | $2.93 | $107.7K | Form 4 |
| 2026-02-27 | Cui Xiangmin | Director | Grant / award / vesting (derivative) | 76,923 | — | $0 | Form 4/A |
Ask the chat about NUVB's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: NUVATION BIO INC CLASS A (NUVB).
Last updated 2026-08-19 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.